BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 26069908)

  • 1. [Peripheral arterial circulatory diseases in young adults].
    Tatò F
    Dtsch Med Wochenschr; 2015 Jun; 140(12):870-3. PubMed ID: 26069908
    [No Abstract]   [Full Text] [Related]  

  • 2. [Inflammatory bowel diseases--new therapeutic options].
    Herrlinger K; Stange EF
    Med Klin (Munich); 2008 Feb; 103(2):90-101; quiz 102-3. PubMed ID: 18270665
    [No Abstract]   [Full Text] [Related]  

  • 3. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
    Moum B
    Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118
    [No Abstract]   [Full Text] [Related]  

  • 4. [Drug therapy of inflammatory bowel diseases].
    Silvennoinen J; Niemelä S
    Duodecim; 1999; 115(20):2233-8. PubMed ID: 11973927
    [No Abstract]   [Full Text] [Related]  

  • 5. Takayasu's aortitis and infliximab.
    El-Matary W; Persad R
    J Pediatr; 2009 Jul; 155(1):151. PubMed ID: 19559311
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination biological and surgical therapy in an adolescent presenting with highly destructive perianal Crohn disease.
    Klinger A; Schursky M; Rosh J; Starker I; Mercer GO; Rolandelli RH
    J Pediatr Gastroenterol Nutr; 2010 Dec; 51(6):784-6. PubMed ID: 20601909
    [No Abstract]   [Full Text] [Related]  

  • 7. [Monoclonal antibodies in multiple sclerosis].
    Papeix C; Lubetzki C
    Med Sci (Paris); 2009 Dec; 25(12):1113-5. PubMed ID: 20035688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab vs. etanercept in psoriasis.
    Downs AM
    Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
    [No Abstract]   [Full Text] [Related]  

  • 9. [New therapy in inflammatory bowel disease (infliximab)].
    Yoshizawa S; Hibi T
    Nihon Rinsho; 2008 Jul; 66(7):1279-85. PubMed ID: 18616118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-inflammatory agents in peripheral arterial disease.
    Antonopoulos AS; Papanikolaou E; Vogiatzi G; Oikonomou E; Tousoulis D
    Curr Opin Pharmacol; 2018 Apr; 39():1-8. PubMed ID: 29169069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monoclonal antibodies in chronic autoimmune inflammatory diseases].
    Semerano L; Boissier MC
    Med Sci (Paris); 2009 Dec; 25(12):1108-12. PubMed ID: 20035687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term outcome of infliximab and other medications on patients with inflammatory bowel disease undergoing ileostomy reversal.
    Regadas FS; Pinto RA; Murad-Regadas SM; Canedo JA; Leal M; Nogueras JJ; Wexner SD
    Colorectal Dis; 2011 May; 13(5):555-60. PubMed ID: 20070344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dacryoadenitis, an extra-intestinal manifestation of Crohn's disease.
    Wong JC; Rossman D; Bressler B
    Am J Gastroenterol; 2010 Aug; 105(8):1904-6. PubMed ID: 20686473
    [No Abstract]   [Full Text] [Related]  

  • 14. [Top-down versus Step-Up: new strategies in the treatment of Crohn's disease].
    Meier J; Sturm A
    Z Gastroenterol; 2009 Feb; 47(2):240-2. PubMed ID: 19197829
    [No Abstract]   [Full Text] [Related]  

  • 15. [CED therapy with infliximab. Rapid and lasting remission - complete mucosal healing].
    Wedekind S
    MMW Fortschr Med; 2011 Dec; 153(48):54-5. PubMed ID: 22299262
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapy of ulcerative colitis].
    Vavricka SR; Rogler G
    Praxis (Bern 1994); 2009 Feb; 98(4):209-12. PubMed ID: 19224489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Isolation of antibodies to Chlamydia and Mycoplasma pneumoniae during the immunosuppressive therapy of patients with inflammatory bowel disease].
    Sagynbaeva VE; Lazebnik LB; Kniazev OV; Parfenov AI; Efremov LI
    Eksp Klin Gastroenterol; 2012; (3):40-6. PubMed ID: 22830223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The return of investment of translational research in inflammatory dermatoses.
    van de Kerkhof PC
    J Dermatolog Treat; 2008; 19(6):317. PubMed ID: 18982511
    [No Abstract]   [Full Text] [Related]  

  • 19. Sensorineural hearing loss in ankylosing spondylitis treated with TNF blockers.
    Savastano M; Marioni G; Giacomelli L; Ramonda R; Ferraro SM; Punzi L
    B-ENT; 2010; 6(3):183-8. PubMed ID: 21090160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].
    Hellström PM; Schmidt D; Karlén P
    Lakartidningen; 2007 Oct 10-16; 104(41):2973-6. PubMed ID: 17977308
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.